glucose, (beta-d)-isomer has been researched along with Severe Acute Respiratory Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, J; Fu, L; Huang, J; Huang, W; Hui, M; Jiang, H; Li, C; Li, R; Li, X; Liu, B; Ma, Q; Pan, W; Shi, Y; Wang, Z; Xie, Y; Yang, Z; Zheng, K | 1 |
| Kaur, U; Mishra, A; Singh, A | 1 |
2 other study(ies) available for glucose, (beta-d)-isomer and Severe Acute Respiratory Syndrome
| Article | Year |
|---|---|
Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Coronavirus; Coronavirus 229E, Human; Coronavirus Infections; COVID-19; Cytokines; Forsythia; Glucosides; Humans; NF-kappa B; Pandemics; Phytotherapy; Plant Extracts; Pneumonia, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; Signal Transduction; Vero Cells; Virus Replication | 2020 |
Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study.
Topics: Amino Acid Sequence; COVID-19; Flavonols; Glucosides; Humans; Molecular Docking Simulation; Peptide Fragments; Severe Acute Respiratory Syndrome | 2022 |